Kestrel Therapeutics received FDA clearance of an IND for KST‑6051, an oral small‑molecule pan‑KRAS inhibitor targeting KRAS‑driven cancers, and plans to start a first‑in‑human Phase I FALCON study by the end of the quarter. The program aims to address tumors driven by various KRAS mutations with a non‑selective approach. KST‑6051’s oral route and pan‑KRAS profile position it to compete in a crowded KRAS landscape that includes mutation‑selective inhibitors and emerging degraders. The IND clearance enables dose‑escalation and safety evaluation in advanced solid tumors, underpinning Kestrel’s clinical and partnering strategy. In oncology development terms: an IND clearance permits initiation of human trials after the FDA reviews preclinical safety, manufacturing, and protocol elements; early clinical data will determine competitive differentiation versus G12C‑ and G12D‑selective agents.